192 related articles for article (PubMed ID: 31141643)
21. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Worley MV; Estrada SJ
Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.
Mbuagbaw L; Guglielmetti L; Hewison C; Bakare N; Bastard M; Caumes E; Fréchet-Jachym M; Robert J; Veziris N; Khachatryan N; Kotrikadze T; Hayrapetyan A; Avaliani Z; Schünemann HJ; Lienhardt C
Emerg Infect Dis; 2019 May; 25(5):936-943. PubMed ID: 31002070
[TBL] [Abstract][Full Text] [Related]
23. A case of primary multidrug-resistant pulmonary tuberculosis with high minimum inhibitory concentration value for bedaquiline.
Kobayashi M; Motoki Y; Yamagishi T; Hirano H; Nonaka M; Aono A; Mitarai S; Saito T
J Infect Chemother; 2022 Aug; 28(8):1193-1197. PubMed ID: 35550867
[TBL] [Abstract][Full Text] [Related]
24. Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope.
Prasad R; Gupta N; Banka A
Indian J Med Res; 2017 Sep; 146(3):301-303. PubMed ID: 29355135
[No Abstract] [Full Text] [Related]
25. Reply to comments by Kakkar and Dahiya.
Chahine EB; Karaoui L; Mansour H
Ann Pharmacother; 2014 May; 48(5):667. PubMed ID: 24733170
[No Abstract] [Full Text] [Related]
26. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153
[TBL] [Abstract][Full Text] [Related]
27. atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure.
Le Ray LF; Aubry A; Sougakoff W; Revest M; Robert J; Bonnet I; Veziris N; Morel F
Emerg Infect Dis; 2022 May; 28(5):1062-1064. PubMed ID: 35447056
[TBL] [Abstract][Full Text] [Related]
28. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
Pontali E; Sotgiu G; Tiberi S; Tadolini M; Visca D; D'Ambrosio L; Centis R; Spanevello A; Migliori GB
Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29903862
[No Abstract] [Full Text] [Related]
29. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
Zhao Y; Fox T; Manning K; Stewart A; Tiffin N; Khomo N; Leslie J; Boulle A; Mudaly V; Kock Y; Meintjes G; Wasserman S
Clin Infect Dis; 2019 Apr; 68(9):1522-1529. PubMed ID: 30165431
[TBL] [Abstract][Full Text] [Related]
30. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
[TBL] [Abstract][Full Text] [Related]
31. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
Chahine EB; Karaoui LR; Mansour H
Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
[TBL] [Abstract][Full Text] [Related]
32. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
[TBL] [Abstract][Full Text] [Related]
33. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
[TBL] [Abstract][Full Text] [Related]
34. Frequent acquisition of bedaquiline resistance by epidemic extensively drug-resistant Mycobacterium tuberculosis strains in Russia during long-term treatment.
Mokrousov I; Akhmedova G; Molchanov V; Fundovnaya E; Kozlova E; Ostankova Y; Semenov A; Maslennikova N; Leontev D; Zhuravlev V; Turkin E; Vyazovaya A
Clin Microbiol Infect; 2021 Mar; 27(3):478-480. PubMed ID: 32891766
[No Abstract] [Full Text] [Related]
35. First 2 Extensively Drug-Resistant Tuberculosis Cases From Myanmar Treated With Bedaquiline.
Aung HL; Nyunt WW; Fong Y; Cook GM; Aung ST
Clin Infect Dis; 2017 Aug; 65(3):531-532. PubMed ID: 28444149
[No Abstract] [Full Text] [Related]
36. Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis.
Perumal R; Bionghi N; Nimmo C; Letsoalo M; Cummings MJ; Hopson M; Wolf A; Jubaer SA; Padayatchi N; Naidoo K; Larsen MH; O'Donnell M
Eur Respir J; 2023 Dec; 62(6):. PubMed ID: 37945030
[TBL] [Abstract][Full Text] [Related]
37. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.
Hafkin J; Hittel N; Martin A; Gupta R
Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30361253
[No Abstract] [Full Text] [Related]
38. Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia.
Martinez E; Hennessy D; Jelfs P; Crighton T; Chen SC; Sintchenko V
Tuberculosis (Edinb); 2018 Jul; 111():31-34. PubMed ID: 30029911
[TBL] [Abstract][Full Text] [Related]
39. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.
Almeida D; Ioerger T; Tyagi S; Li SY; Mdluli K; Andries K; Grosset J; Sacchettini J; Nuermberger E
Antimicrob Agents Chemother; 2016 Aug; 60(8):4590-9. PubMed ID: 27185800
[TBL] [Abstract][Full Text] [Related]
40. The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report.
Park S; Lee KM; Kim I; Mok J
Int J Infect Dis; 2018 Nov; 76():88-90. PubMed ID: 30244076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
